Startseite › Nichtkleinzelliges Lungenkarzinom › Delaware › Newark
Klinische Studien zu Nichtkleinzelliges Lungenkarzinom in Newark, DE
16 Studien zu Nichtkleinzelliges Lungenkarzinom suchen Teilnehmer an Standorten in und um Newark (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- Medical Oncology Hematology Consultants, Newark
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Teilnehmer gesuchtPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Teilnehmer gesuchtPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Teilnehmer gesuchtPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Teilnehmer gesuchtPhase 3
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 2
- ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 2
- ChristianaCare Health System, Newark
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Research Site, Newark
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Teilnehmer gesuchtPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Research Site, Newark
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Teilnehmer gesuchtPhase 3
- Research Site, Newark
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2/3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Teilnehmer gesuchtBeobachtungsstudie
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- Christiana Care - Union Hospital, Elkton · 7 mi entfernt
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Newark
Nichtkleinzelliges Lungenkarzinom-Studien in anderen Städten
- Houston, TX145 Studien
- New York City, NY120 Studien
- Arlington, VA104 Studien
- Nashville, TN97 Studien
- Boston, MA90 Studien
- Los Angeles, CA87 Studien
- St. Louis, MO73 Studien
- Chicago, IL61 Studien
- Baltimore, MD60 Studien
- San Antonio, TX59 Studien
- Columbus, OH56 Studien
- Washington, DC55 Studien
Weitere Studien in Newark
- Prostatakrebs10 Studien
- Kolorektales Karzinom9 Studien
- Lungenkrebs9 Studien
- Brustkrebs8 Studien
- Metastasierender Krebs7 Studien
- Krebs (alle Arten)6 Studien
- Bauchspeicheldrüsenkrebs6 Studien
- Eierstockkrebs5 Studien
- Follikuläres Lymphom4 Studien
- Chronische lymphatische Leukämie4 Studien
- Magenkrebs4 Studien
- Melanom4 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.